In 2008, a group led by Prof. Marcos Tobias-Machado, initiated a research series involving the role of the human epidermal growth factor receptor extracellular domain (HER-2/neu) in patients with prostate cancer. First, in an initial sample of 30 patients, there was found to be a strong correlation between levels of this marker and diagnosis of prostate cancer. In further analysis, it was also seen that high levels of HER-2/neu extracellular domain were correlated with tumor aggressiveness, represented by higher levels of PSA and a moderate/high D'Amico score. Further to these results, Dr... 
More...
More...